{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is CureVac NV overvalued or undervalued?
As of October 24, 2025, CureVac NV is considered a very attractive investment due to its undervaluation indicated by a P/E ratio of 5, an EV to EBITDA of 1.90, and a PEG ratio of 0.03, despite a long-term decline of 89.29% over five years, while outperforming the S&P 500 with a year-to-date return of 57.18%.
Is CureVac NV overvalued or undervalued?
As of October 24, 2025, CureVac NV is considered very attractive due to its low P/E ratio of 5, strong recent performance with a 57.18% year-to-date return, and favorable valuation metrics, indicating it is undervalued compared to peers.
Is CureVac NV overvalued or undervalued?
As of October 24, 2025, CureVac NV is considered very attractive due to its undervaluation indicated by a P/E ratio of 5, an EV to EBITDA ratio of 1.90, and a PEG ratio of 0.03, significantly outperforming peers and delivering a year-to-date return of 57.18% compared to the S&P 500's 15.47%.
Is CureVac NV technically bullish or bearish?
As of August 18, 2025, CureVac NV's trend is mildly bullish with mixed technical indicators, strong year-to-date performance of 56.89%, but negative long-term returns compared to the S&P 500.
Is CureVac NV overvalued or undervalued?
As of September 12, 2025, CureVac NV's valuation has improved to very attractive, with a significantly low P/E ratio of 5 and strong year-to-date performance of 56.89%, indicating it is undervalued compared to industry peers despite recent short-term volatility.
CureVac NV Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics
CureVac NV, a small-cap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics. With a P/E ratio of 5 and strong returns on capital and equity, the company demonstrates operational efficiency and profitability, positioning itself competitively against peers in the industry.
Is CureVac NV overvalued or undervalued?
As of June 13, 2025, CureVac NV is considered an attractive investment due to its undervalued financial metrics, including a P/E ratio of 5 and an EV to EBITDA of 1.90, alongside strong stock performance that has outpaced the S&P 500.
Is CureVac NV technically bullish or bearish?
As of May 21, 2025, CureVac NV's trend has shifted to bullish with moderate strength, supported by bullish indicators like the MACD and moving averages, although the weekly RSI suggests some short-term weakness.
What does CureVac NV do?
CureVac NV is a Germany-based biotechnology company focused on developing mRNA and RNA-based vaccines for infectious diseases, cancer, and rare diseases. As of March 2025, it reported net sales of $1 million and a net loss of $55 million, with a market cap of $1.24 billion.
How big is CureVac NV?
As of Jun 18, CureVac NV has a market capitalization of 1,238.36 million, with net sales of 574.48 million and a net profit of 203.49 million over the latest four quarters. The company reported shareholder's funds of 721.34 million and total assets of 831.33 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
